Linking EHR and Genomic Data to Evaluate Patterns of Care
Linking EHRs with genomic profiling data from patients with NSCLC supported associations seen in clinical trials.
Non-Small Cell Lung Cancer
Keytruda Gains Expanded Monotherapy Indication for First-Line Treatment of NSCLC
Merck announced that the Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
Apparent Immunotherapy-Induced Hyperprogression in a Patient With Stage III NSCLC
A number of different definitions of immunotherapy-related hyperprogression are currently in use.
Dual Immunotherapy and an Emerging Biomarker in NSCLC
Data from a phase 2 trial of nivolumab + ipilimumab in NSCLC suggest that tumor mutational burden may be a superior biomarker to PD-L1 expression.
Hyperprogression During Immunotherapy: Teasing Out the Mechanism
A preclinical study highlights the potential role the Fc receptor may play in mediating hyperprogressive disease, but further study is needed.
Prophylactic Cranial Irradiation Not Associated With Improved OS in Locally Advanced NSCLC
Prophylactic brain irradiation was associated with a significant improvement in disease-free survival and a significant reduction in likelihood of developing brain metastases.
Time to Treatment Discontinuation Makes Headway as Real-World End Point
An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.
ALK‐ vs EGFR‐Positive NSCLC: CT Imaging and Clinical Characteristics
NSCLC characterized by ALK or EGFR molecular alterations produced different findings on CT scan images.
Genomic Profiling Using Guardant 360 Cell-Free DNA-Based Assay vs Tumor-Based Genotyping Assays in Advanced NSCLC
The Guardant360 assay is as effective as traditional tumor-based genotyping assays in identifying genomic alterations, according to researchers.
Overall Survival in Patients With Stage IV ALK-Positive Non-Small Cell Lung Cancer Treated With Crizotinib
Researchers found that survival was associated with the number of metastatic sites, but not affected by brain metastasis.
Next post in Lung Cancer
